Aflibercept (Eylea)

Eylea (aflibercept) is authorized for FDA‑approved ocular indications (neovascular/wet AMD, macular edema from RVO, DME, DR) and select compendial off‑label neovascular ophthalmic conditions, with other uses not supported. Approvals require documented diagnosis and meeting indication‑specific coverage guidelines, administration by or under an ophthalmologist’s supervision, adherence to the specified dosing schedules (e.g., AMD: 2 mg q4wk ×3 then q8wk; RVO: 2 mg q4wk; DME/DR: 2 mg q4wk ×5 then q8wk), and are issued for up to 12 months.

"Neovascular (wet) age-related macular degeneration (AMD)"

Sign up to see full coverage criteria, indications, and limitations.